Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer.
Hira Shaikh(University of Iowa Hospitals and Clinics), Trisha M. Wise‐Draper(University of Cincinnati), Pavel Brodskiy(Caris Life Sciences (United States)), Jim Abraham(Caris Life Sciences (United States)), Jennifer L. Leddon(University of Cincinnati), Julie McGrath(Caris Life Sciences (United States)), Joanne Xiu(Caris Life Sciences (United States)), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Dan P. Zandberg(University of Pittsburgh Medical Center)
Cited by 1
Related Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
|Annals of Oncology|2021|328